1. Introduction
===============

Bladder tumor is the second most common urological malignancy and has been a growing healthcare problem all over the world.^\[[@R1]--[@R4]\]^ To date, radical surgery was the most effective treatment.^\[[@R5],[@R6]\]^ For nonmuscle invasive bladder carcinoma (NMIBC), transurethral resection of bladder tumor (TURBT) remains the standard treatment.^\[[@R7]\]^ Unfortunately, bladder tumor is bound up with high recurrence rates (50%--70%) after transurethral resection management, and tumor cell implantation is deemed to be a major cause of early recurrence.^\[[@R8],[@R9]\]^ Thus, it is reasonable to modify TURBT to provide en bloc transurethral resection of bladder tumor (ETURBT) of the specimen, based on the established oncological principle of dissecting through normal tissue.^\[[@R10]\]^ Several studies have examined the efficacy and feasibility of en bloc TURBT.^\[[@R11]--[@R16]\]^ In this study, a meta-analysis was performed to evaluate the efficacy and feasibility of ETURBT for the participants with NMIBC compared with conventional TURBT.

2. Materials and methods
========================

2.1. Ethics statement
---------------------

Ethical approval was not required for this meta-analysis. It is a meta-analysis which has not affected participants directly.

2.2. Study selection
--------------------

We searched MEDLINE, EMBASE, Cochrane Library, Web of Science, and Google scholar databases for articles published before September 12, 2016. A combination of search terms was used including "en bloc resection", "transurethral resection", "bladder tumor", "bladder cancer", "TURBT", and "cystectomy". The search was conducted with a language restricted to English publication.

2.3. Selection criteria
-----------------------

The inclusion criteria were as follows: original articles in English publication; trials reporting individual demographic, survival information, and clinical follow-up data; and trials comparing the efficacy and feasibility of ETURBT versus conventional transurethral resection of bladder tumor (CTURBT) in NMIBC. Single-arm trials, case reports, and systematic reviews were excluded.

2.4. Data extraction
--------------------

Two investigators (Y-PW and S-HC) extracted data, respectively, employing a predefined data extraction form. Subsequent full-text record screening was fulfilled independently by 2 investigators (Y-PW and S-HC). Disagreements were resolved by a third reviewer (NX). All of the included trials in our meta-analysis contain data as follows: first author\'s name, published year, surgical method, number of patients, median age, operation time (OT), hospitalization time (HT), catheterization time (CT), 24-month recurrence rate (24-month RR), recurrence-free survival (RFS), and complications. We made several attempts to contact the corresponding authors to obtain the necessary data to meet inclusion criteria, when their studies did not meet inclusion requirements. At least 3 follow-up attempts were made for queries sent; unfortunately, these attempts were unsuccessful.

2.5. Statistical analysis
-------------------------

Statistical analysis was conducted utilizing RevMan5.3 (Cochrane Collaboration, Oxford, UK). Chi-square and *I*^2^ tests were employed to test the heterogeneity of different trials^\[[@R17],[@R18]\]^; no heterogeneity existed when *P* \> 0.1 and *I*^2^ \< 50%, a fixed-effects model was applied to pool the trial results. Significant heterogeneity was identified if *P* \< 0.1 and *I*^2^ \> 50%, and a random-effects model was employed.^\[[@R19]\]^ OT, HT, and CT were determined applying continuous variables. Complications and 24-month RR were determined applying dichotomous variables. Subgroup analysis of postoperative adjuvant intravesical chemotherapy was also determined applying dichotomous variables. RFS was calculated using effect variables. Hazard ratios (HRs) with 95% confidence interval (CI) were extracted from the survival curves when HRs were unavailable for RFS.^\[[@R20]\]^ Sensitivity analysis and publication bias analysis were conducted utilizing Stata 12.0 (Stata-Corp, College Station, TX). Begg funnel plot and Egger test were used to identify whether publication bias existed.

3. Results
==========

3.1. Workflow of literature research
------------------------------------

There were 304 potential relevant studies in the primary literature search, and 22 duplicate studies existed. After removing the duplicate studies, 258 studies were further excluded by reading the title and abstract. Then, a total of 17 additional studies were removed by 2 authors (Y-PW and S-HC) independently reading the full text. Therefore, 7 studies were included in this meta-analysis.^\[[@R11]--[@R16]\]^ We described study procedure\'s details in Fig. [1](#F1){ref-type="fig"}. Two authors (Y-PW and S-HC) independently completed this work, and any disagreements were dealt with by discussion.

![Flow diagram for selection of the included trials reviewed.](medi-95-e5372-g001){#F1}

3.2. Study characteristics
--------------------------

These included studies recruited 886 participants with various stages of bladder cancer comprising 438 cases that underwent ETURBT and 448 with CTURBT. The demographics of enrolled individuals and tumor characteristics are presented in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, respectively. All of the cases applied postoperative installation therapy, mitomycin was used in 3 trials,^\[[@R11],[@R15],[@R16]\]^ and epirubicin was used in 4 trials.^\[[@R12]--[@R14]\]^
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Characteristics of trials included in the meta-analysis.
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Tumor characteristics.
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3.3. Operation time, hospitalization time, and catheterization time
-------------------------------------------------------------------

OT was available for 6 trials^\[[@R11]--[@R14],[@R16]\]^ (Fig. [2](#F2){ref-type="fig"}A). The pooled weight mean difference (MD) was 1.92 (95% CI = −2.33 to 6.18; *I*^2^ = 79%; *P* = 0.38), indicating that there was no significant difference between ETURBT and CTURBT. HT and CT was available for all 7 trials^\[[@R11]--[@R16]\]^ (Fig. [2](#F2){ref-type="fig"}B and C). The pooled weight MD was −1.22 (95% CI = −1.63 to −0.80; *I*^2^ = 82%; *P* \< 0.01) and MD was −0.61 (95% CI = −1.11 to −0.11; *I*^2^ = 92%; *P* = 0.02), indicating that ETURBT yielded a shorter HT and CT over CTURBT. However, there was a significant heterogeneity existing (*I*^2^ = 82% and 92%). Thus, a random model was applied, and further discussion was made to explain the heterogeneity.

![Forest plot comparing operation time (A), hospitalization time (B), catheterization time (C), 24-month recurrence rate (D), and recurrence-free survival (E).](medi-95-e5372-g004){#F2}

3.4. 24-month recurrence rate and recurrence-free survival
----------------------------------------------------------

Analysis showed that there was a significant difference in 24-month RR reported by 6 trials.^\[[@R11],[@R13]--[@R16]\]^ The pooled odds ratio (OR) was 0.66 (95% CI = 0.47--0.92; *I*^2^ = 0; *P* = 0.02) (Fig. [2](#F2){ref-type="fig"}D). Three trials^\[[@R11],[@R12],[@R16]\]^ reported RFS, and there was no significant difference between two arms, the pooled OR was 0.81 (95% CI = 0.53--1.25; *I*^2^ = 0; *P* = 0.34) (Fig. [2](#F2){ref-type="fig"}E).

3.5. Complications
------------------

Four trials^\[[@R13]--[@R15]\]^ reported obturator nerve reflex, and 4 trials^\[[@R11],[@R13]--[@R15]\]^ reported bladder perforation, respectively. The pooled OR was 0.04 (95% CI = 0.01--0.15; *I*^2^ = 0; *P* \< 0.01) and 0.14 (95% CI = 0.04--0.54; *I*^2^ = 0; *P* = 0.004) (Fig. [3](#F3){ref-type="fig"}A and B), respectively, which indicated that ETURBT may cause less bladder perforation than CTURBT. Four trials^\[[@R13]--[@R15]\]^ reported bladder irritation and 3 trials^\[[@R11],[@R13],[@R15]\]^ reported urethral stricture, respectively. The pooled OR was 0.22 (95% CI = 0.11--0.43; *I*^2^ = 55%; *P* \< 0.01) and 0.57 (95% CI = 0.16--2.06; *I*^2^ = 0; *P* = 0.39) (Fig. [3](#F3){ref-type="fig"}C and D), respectively, which indicated that ETURBT may cause less obturator nerve reflex and bladder irritation than CTURBT.

![Forest plot comparing complications in terms of obturator nerve reflex (A), bladder perforation (B), bladder irritation (C), and urethral stricture (D).](medi-95-e5372-g005){#F3}

3.6. Sensitivity analysis and publication bias
----------------------------------------------

A sensitivity analysis was performed by deleting a study at a time to assess the influence of an individual study on synthetic statistics. In terms of HT, when Liu trial^\[[@R13]\]^ was removed, *I*^2^ altered from 82% to 68%. In addition, when Xu trial^\[[@R12]\]^ was removed, *I*^2^ altered from 82% to 77%. When both trials^\[[@R12],[@R13]\]^ were removed, the overall results altered obviously, *I*^2^ altered from 82% to 43%, which indicated that those 2 studies should be responsible for the heterogeneity of our eligible statistics. The reason could be explained as follows: the study type of Xu trial^\[[@R12]\]^ was a randomized controlled trial, it is different from other eligible studies. Moreover, when Chen trail^\[[@R11]\]^ was removed with respect to OT, *I*^2^ altered from79% to 60%, this heterogeneity could be explained by the laser type. Chen trail performed ETURBT using green-light laser, and other trails included performed ETURBT using holmium laser or 2-μm continuous-wave laser. In addition, publication bias was evaluated by Begg funnel plot and Egger test, and no obvious biases were identified.

4. Discussion
=============

To the best of our knowledge, this study is the first meta-analysis with a focus on comparing the efficacy and feasibility between ETURBT and CTURBT. It remains controversial whether the actual potential of ETURBT resides more in the therapeutic or diagnostic sector.^\[[@R21],[@R22]\]^ On one hand, CTURBT is dependent on in situ tumor fragmentation for tumor removal and specimen retrieval, and basic oncological surgical tenet was violated by CTURBT. This practice will promote tumor cell dispersal, and the pathological integrity of the specimen will be jeopardized.^\[[@R21]\]^ On the other hand, well controlled resection of the whole tumor was yield, and the detrusor muscle present in the specimen was significantly better with ETURBT due to better visualization.^\[[@R10]\]^ Therefore, this meta-analysis was performed to systematically evaluate these 2 techniques, providing evidence for the optimal treatment of NMIBC.

After combining results from 6 studies consisting of 7 trials, no significant trend of decreased OT in patients treated with ETURBT than CTURBT was observed. There were statistically significant differences in HT and CT between ETURBT and CTURBT. Moreover, it appeared that patients who underwent ETURBT experienced significant reductions in 24-month RR. But in terms of RFS, there was no statistically significant difference between the 2 arms. The complications including bladder perforation, obturator nerve reflex, and bladder irritation were less in ETURBT. No statistically significant difference in urethral stricture rate was noted. The CT and HT in ETURBT were less than that in CTURBT. However, the heterogeneity in pooled HT and CT should not be ignored (*I*^2^ = 82%, *P* \< 0.001 and *I*^2^ = 92%, *P* \< 0.001). There are several reasons for those differences: first of all, the high heterogeneity indicated that these differences might be unrelated to the technique itself, there are plenty of confounding factors that should be taken into account^\[[@R11]\]^; second, in personal comprehension, patient demographics and tumor characteristics are different, further researches should be done to ascertain the affect factors; third, previous studies^\[[@R11]--[@R13]\]^ demonstrated that ETURBT may have some advantages in terms of perioperative complication rates. Our meta-analysis indicated that ETURBT may cause less bladder perforation, obturator nerve reflex, and shorter durations of postoperative bladder irritation than CTURBT. Moreover, 2 kinds of study type were pooled (retrospective study and prospective study), some bias may exist in this procedure, which would increase the heterogeneity of outcome and diminish the validity of our study. Finally, patients underwent surgery in different hospitals, different hospitals possessed different medical levels.

Staging quality was determined by the condition of detrusor muscle presented in specimens and demonstrated complete resection.^\[[@R11]\]^ Complete resection of the pathologic specimen plays an important role in bladder tumor transurethral resection, which determines postoperative pathologic diagnosis and prognosis.^\[[@R23]\]^ Unfortunately, the trials enrolled in our study had not provided sufficient information about the data of detrusor muscle-positive specimens. To the best of our knowledge, detrusor muscle-positive specimens in 78% and 100% were reported in 2 small case series,^\[[@R24],[@R25]\]^ and the presence of the detrusor muscle layer in 97.3% of 221 samples was demonstrated by Kramer et al.^\[[@R26]\]^ All of enrolled trials possessed the view that ETURBT can obtain adequate complete tumor specimens, containing the mucosa, lamina propria, and muscle layer for determining pathological diagnosis and treatment procedure.^\[[@R12]\]^

The postoperative adjuvant intravesical chemotherapy was performed for each patient in our meta-analysis. The characteristics of regimen of every trial were demonstrated in Table [3](#T3){ref-type="table"}. The application of postoperative adjuvant intravesical chemotherapy was quite inconsistent in each trial. Three trials^\[[@R11],[@R15],[@R16]\]^ received mitomycin and 4 trials^\[[@R12]--[@R14]\]^ received epirubicin. However, the duration of administration and the drugs administered varied. We performed a subgroup analysis to evaluate the definitive relationship between 24-month RRs and postoperative adjuvant intravesical chemotherapy (Fig. [4](#F4){ref-type="fig"}). In mitomycin group, 3 trials^\[[@R11],[@R15],[@R16]\]^ were enrolled. The results showed a statistical significant difference between 2 arms when mitomycin was postoperatively used (*P* = 0.02). In eprirubicin group, 3 trials^\[[@R13],[@R14]\]^ were included, and there was a statistical significant difference between the 2 arms when eprirubicin was postoperatively used (*P* = 0.43). The subgroup analysis demonstrated that postoperatively used mitomycin might be an important factor which affected the 24-month RRs between ETURBT and CTURBT.
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Postoperative adjuvant intravesical chemotherapy regimen.
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![Subgroup analysis of the 2 groups according to the mitomycin and eprirubicin used for postoperative adjuvant intravesical chemotherapy.](medi-95-e5372-g007){#F4}

There are several limitations of our study. First of all, included trails are consisted of 2 retrospective studies and 4 prospective nonrandomized studies and 1 randomized controlled trial. This certainly attenuated the value of our meta-analysis. Further studies need to be done in the near future. Second, in terms of the small sample size and limited number of studies enrolled, the results may lack statistical power.

5. Conclusion
=============

ETURBT is superior to CTURBT in terms of shorter HT and CT, less complication rate, and lower recurrence-free rate. Moreover, it can provide a better tumor specimen for pathological evaluation. ETURBT is potentially useful alternative to CTURBT. However, this result needs to be validated in further prospective, randomized, controlled studies.

Abbreviations: 24-month RR = 24-month recurrence rate, CI = confidence interval, CT = catheterization time, CTURBT = conventional transurethral resection of bladder tumor, EAU = European association of urology, ETURBT = en bloc transurethral resection of bladder tumor, HRs = hazard ratios, HT = hospitalization time, MD = mean difference, NMIBC = nonmuscle invasive bladder carcinoma, OR = odds ratio, OT = operation time, RFS = recurrence-free survival, SD = standard deviation, TURBT = transurethral resection of bladder tumor.
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